BARCELONA, Spain, a global biopharmaceutical company focused on skin health, and IRB Barcelona (the Institute for Research in Biomedicine), an independent, international research centre engaged in fundamental and applied biomedical science, announced today a research collaboration to identify new oral treatments for immune-inflammatory skin diseases with remaining high unmet medical needs using molecular glue degraders, a novel therapeutic modality. These monovalent degraders offer a new avenue to induce the degradation of potentially disease-causing proteins that cannot be targeted with conventional therapeutic agents. The collaboration brings together Almirall’s scientific, dermatological, and data analysis knowledge with the expertise of the IRB Barcelona’s Targeted
The post Almirall and IRB Barcelona announce a research collaboration to discover novel molecular glue therapeutics for severe skin diseases appeared first on Pharma Mirror Magazine.
